Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry.
<h4>Background</h4>Based on the excellent results of the clinical trials with ALK-inhibitors, the importance of accurately identifying ALK positive lung cancer has never been greater. However, there are increasing number of recent publications addressing discordances between FISH and IHC...
Saved in:
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | article |
Language: | EN |
Published: |
Public Library of Science (PLoS)
2014
|
Subjects: | |
Online Access: | https://doaj.org/article/a2ee3e16eccc4c4487381ac1367b8191 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|